19F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers
2018
Abstract1. Leniolisib is a novel oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor, currently in clinical development for the treatment of inflammatory and autoimmune diseases.2. We investi...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
20
References
2
Citations
NaN
KQI